SELLAS Life Sciences (SLS) Interest Expenses (2011 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Interest Expenses of $5.8 million for Q1 2026, up 2800.5% year-over-year from $200000.0 in Q1 2025, and up 5701.0% quarter-over-quarter from $100000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Interest Expenses (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Interest Expenses for 16 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 2800.5% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 1060.2% YoY), while the FY2025 annual figure was $22.8 million, up 9.45% from the prior year.
- Interest Expenses rose to $5.8 million in Q1 2026 per SLS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $5.8 million in Q1 2026 and bottomed at $100000.0 in Q1 2022.
- Historically, Interest Expenses has averaged $568058.8 across 5 years, with a median of $100000.0 in 2022.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 50.0% — and 2026, when it jumped 2800.5%.
- SELLAS Life Sciences' Interest Expenses stood at $200000.0 in 2022, then slumped by 50.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then jumped by 5701.0% to $5.8 million in 2026.
- Business Quant data shows SLS's Interest Expenses at $5.8 million in Q1 2026, $100000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 32.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.34 Mn |
| Jun 30, 2026 | 32.34 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |